gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin review expect
continu momentum seen gene therapi gt sinc inde consist predict
chardan gene therapi framework period saw avexi share surg breakthrough result
first us gt approv big biopharma increas gt exposur continu momentum big
gt acquisit revel like breakthrough result xlmtm dmd first rnai therapeut onpattro
approv us europ smaller-cap rare diseas compani join big biopharma increas
gt exposur expect follow theme vivo gt zolgensma pricing/uptak broad
implic fewer deal done academia compani gt exposur emerg
heart viabl primari target tissu data muscl diseas hemophilia continu progress make
gt viabl large-market polygen diseas like wet expans import synthet biolog
promot transgen switch artifici intellig ai greater use steroid mitig toxic
gt outperform figur vivo gt perform aav srna vivo gene
chardan genet medicin alpha portfolio gmap continu gener high alpha
chardan top pick genet medicin figur cumul alpha gener sinc march
chardan genet medicin top pick figur close averag alpha gener
chardan genet medicin top pick figur close averag alpha gener
revieww highlight theme genet medicin togeth made good year
gene therapi fda remain support via new guidelin rac review elimin
gene therapi avexi show disrupt gt compani inde file good part phase data
gene therapi muscl join eye brain/cn liver viabl primari target aav-bas gt
gene therapi despit mix sector signal cost effect pbm gt distribut posit
gene therapi small- large-cap biopharma increasingli lever gt asset
gene therapi efficaci aav gt durabl hit yr safeti system toxic issu rais
gene therapi compani increasingli use steroid mitig immunogen concern
gene edit saw up down vivo crispr gene edit
gene edit new crispr technolog emerg therapeut diagnost use
rnai onpattro first rnai therapeut approv clinic data drive smaller cap
bold predict vivo gt came true thu gener alpha
confirm market cap uniqur buy reach billion mm
confirm avexi buy get acquir breakthrough asset perhap roch unrat
confirm basket foreign-list name sight pa ly pa oxb toolgen outperform nbi
confirm biomarin unrat attempt acquir partner uniqur due variou synergi
previewthi time make one bold predict potenti alpha gener
uniqur get acquir perhap biomarin reach bn market cap bn
chardan genet medicin top pick far includ buy qure buy buy
chardan annual genet medicin confer take place octob new york citi
compani mention report
pleas refer import disclosur inform regul analyst certif found page report
page
review genet medicin show broader util
gene therapi avexi show disrupt compani file good part phase data
gene therapi muscl join liver eye viabl primari target aav-bas gt
gene therapi despit mix sector signal cost-benefit pbm gt distribut
gene therapi small- large-cap biopharma increasingli lever gt asset
gene therapi efficaci durabl hit yr safeti system tox issu rais
gene therapi compani increasingli use steroid mitig immunogen concern
gene edit saw up down vivo crispr gene edit
gene edit new crispr technolog emerg therapeut diagnost use
rnai onpattro first rnai therapeut approv clinic data drive smaller cap
review datasetsselect clinic gm dataset trial first report
review collaborationsselect newly-announc gm collabor
review bn select gm equiti offer ipo secondari
review aroughli bn select gm relat activ
review stock price decemb vs decemb
review monthli market cap progress
chardan anticip theme vivo gt
chardan bold predict uniqur get acquir reach bn market cap
viral news genet medicin chardan publish research
chardan top pick genet medicin avx alpha sinc
chardan genet medicin top pick qure average alpha
chardan genet medicin top pick avx average alpha
select catalyst genet medicin coverag
select catalyst genet medicin coverag
select catalyst outsid genet medicin coverag
page
aav-bas gene therapi comp meiragtx uniqur chardan top pick
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
vivo gene edit comp see greater upsid potenti intellia toolgen
genet medicin therapeut approv fda and/or ema
genet medicin therapeut receiv fda breakthrough therapi ema prime design
prioriti review voucher prv valu prv sold compani compani
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
genet medicin regulatori design btd rmat prime ftd rpdd grant time
page
review genet medicin show broader util
continu theme note decemb review name fda support
promis gt importantli updat draft guidanc clarifi expect manufactur trial
design patient monitor gener also via posit gestur activ dialogu gener toward innov
gene therapi compani juli importantli fda issu new kind draft guidanc
accompani statement commission gottlieb gene therapi hemophilia retin diseas rare diseas
also issu refresh past gt guidelin retrovirus long-term follow see juli research
addit fda show high transpar intent via commun industri may
remark allianc regen medicin arm annual board meet octob public
nation institut nih new england journal medicin elimin recombin
dna advisori committe rac review gene therapi clinic trial togeth guidelin commun
provid import posit theme gene therapi space support view emphasi ad
guidelin sponsor consid designingfirst-in-human stud adequ well-control
investigationto provid evid effect support market applic
guidelin hemophilia gt factor activ may permit surrog endpoint acceler approv
guidelin compani visibl long-term follow-up ltfu requir fda recommend year
integr vector year gene edit product year aav-bas
arm meet fda consid much gt product manufactur gene cassett chang
develop theme benefit uniqur previous compani octob announc
relat transit highly-act padua variant hemophilia gt
arm meet fda acknowledg question durabl responseoften cant fulli answer
reason size pre-market trial use registri real-world evid like play increasingli
import role fda thu ask resourc greatli expand capabl forpost market data
arm meet fda begun help industri improv manufactur yield collabor help
improv yield cell line use produc gene therapi vector investig applic advanc
manufactur technolog continu manufactur develop scalabl manufactur process
inher qualiti attribut potenti support scale licensur
nejm public fda commission gottlieb nih director articl date octob explain
propos made august feder regist elimin rac review report requir
nih human gt protocol propos base view senior leader fda nih
longer suffici evid claim risk gene therapi entir uniqu unpredict
gene therapi avexi show disrupt compani file good part phase data
discuss previous octob research potenti gene therapi compani file phase
i/ii trial result lack treatment option gene therapi produc result subtl
often highlight potenti avexi file phase data januari avexi novarti compani
announc base end-of-phas meet reach align fda proceed toward file bla
aav-bas gt zolgensma spinal muscular atrophi type sma novarti later acquir avexi trial
page
decemb announc fda file accept prioriti review base data phase zolgensma start
januari novarti plan us japan zolgensma launch europ
gene therapi muscl join liver eye viabl primari target aav-bas gt
notabl success investor attent aav-bas gt target eye brain/cn liver primari target
muscl also becam signific investor focu due work compani like audent therapeut solid
bioscienc even larger cap gt player like signific exposur muscl
primari target on-going work clinic see figur audent rmat- prime-design
gt x-link myotubular myopathi xlmtm sarepta gt
duchenn muscular dystrophi dmd produc pioneer data tissu administr
demonstr robust transduct protein express normal report octob level
express translat clinically-meaning motor function gain treat patient abl sit
independ respiratori function improv patient achiev ventil independ sarepta show
similarli impress data dmd day june addit follow-up octob patient
treat show micro-dystrophin express normal adjust fat
fibrot tissu led mark improv ambul patient even regain abil climb
stair jump data drove consider movement sarepta market cap year bn decemb
bn decemb gain social media report dmd patient treat aav-bas
 may june suggest asset
may way gener similarli remark result sarepta despit seriou advers event solid first
patient result clinic hold march subsequ patient treatment-associ respons
control treat patient well novemb updat believ social media report
interpret high amount caution may still on-going sourc earli insight clinic trial data
subsequ stock move given avexi stock move seen previous facebook video zolgensma patient
walk note sarepta success dmd gt consist competitor therapeut august
complet acquisit privat gt capabl registration-stag aav-bas gt
aadc defici pipelin aav-bas
adapt wang et al adeno-associ viru vector platform gene therapi deliveri drug disc
figur aav-bas gene therapi trial list clinicaltri govmuscl one investig tissu target
page
gene therapi despit mix sector signal cost-benefit pbm gt distribut
price uptak zolgensma sma type import vivo gt space novarti
novemb investor updat per slide present value-bas price model aav-bas gt zolgensma
registr treat sma may see approv base quality-adjust life year qali calcul
novarti determin drug cost one-tim treatment zolgensma cost effect rang
million say mm price zolgensma fall much rang qualiti gain
signific rare diseas product interestingli nation institut excel
institut clinic econom review icer draft scope/evid document exist zolgensma icer exampl
note zolgensma placehold price million estim increment cost-effect health care
sector perspect patient symptomat type sma per qali gain estim cost per ly gain
result virtual ident modifi societ perspect mm roughli amount
model march avexi initi base qali analysi justifi mm one-tim zolgensma price
luxturna iter found best-cas scenario cost effect eye januari
report luxturna would price total eye spark also announc new access
program spread payment time includ outcomes-bas rebat arrang icer weigh luxturna
cost effect revis conclus substanti price discount need tradit cost-effect
standard updat evid report januari posit broader benefitsto affect individu
societi provid reason long-term valu despit high price final evid report februari though
seri analys suggest luxturna would cost effect lower price icer ultim found
best-cas scenario receiv luxturna provid long-term benefit valu would approach
list price also saw cost-effect commentari genet medicin gm kymriah icer
us import posit specialti pharma busi pbm distribut one-tim pharmaci
benefit manag pbm like express script import gatekeep lucr us therapeut market
organiz support expens gt therapi posit space august articl reuter
commun express script exclus distribut right spark luxturna spinraza
compani also help manag novarti kymriah negoti on-going express script lead gt player
biomarin pharmaceut bluebird bio express script steve miller state partnership gt
compani help expens therapi succeed commerci inde exclus distribut arrang
gt compani us give pbm organ econom reason support block disrupt associ real
valu assum conflict interest pbm organ negoti gt price partner gt compani
manag littl bad press emerg believ news clear posit gt industri
gene therapi small- large-cap biopharma increasingli lever gt asset
cap name acquir gene therapi name gilead-kit celgene-juno novartis-avexi us
import tangibl signal emerg broader gene therapi space notabl merger acquisit
activ occur sinc august announc acquir ex vivo gene-modifi cell therapi
compani kite pharma billion shortli thereaft januari celgen corpor announc
page
acquisit kite peer juno therapeut approxim billion april novarti announc
acquisit vivo gene therapi compani avexi billion
follow smaller-cap bio pharma compani invest gene therapi well perhap noteworthi
larger acquisit move smaller player target genet diseas transit develop
tradit therapeut also develop gene therapi note octob ultragenyx
potenti anticip trend announc acquisit dimens
follow number compani show increas exposur gt also genet medicin gm asset
sarepta us perhap best exampl far multi-year valu accret consequ rare
diseas compani transit gt notabl sarepta announc gt deal muscular dystrophi
octob myonexu therapeut may sarepta expand gt market announc
collabor lacerta therapeut august nch octob lysogen octob
furthermor prepar commerci opportun sarepta announc manufactur partnership brammer
june paragon servic octob aldevron januari sarepta market cap per
factset parallel gone bn decemb bn decemb bn
peak septemb bn decemb sarepta ahead curv
gt busi develop stock perform dmd gt asset suggest believ investor consid
whether sarepta partnership signal broader emerg gt
perhap best known dmd product juli announc agreement acquir agili
biotherapeut late-stag aav-bas gt compani mm mm agili develop pre-bla gt
candid gt-aadc aadc defici preclin candid friedreich ataxia angelman syndrom
amicu septemb announc acquisit celenex mm up-front
mm total clinic preclin asset neurolog lysosom storag disord octob
amicu announc enter collabor professor wilson lab univers pennsylvania upenn
develop aav-bas gene therapi metabol diseas like pomp fabri
axov scienc june announc licens clinic lvv-base gt axo-lenti-pd parkinson diseas
oxford biomedica juli compani announc licens axo-aav-opmd preclin aav-bas
gt oculopharyng muscular dystrophi opmd benitec biopharma decemb compani
announc licens right gangliosidosi univers massachusett medic school
umm compani novemb announc hire support gt pipelin
roivant scienc aruv axov genev urov roivant increas portfolio exposur genet medicin
addit roivant new gt exposur busi unit axov note new gt/gm exposur
elsewher august urov scienc roivant compani launch announc licens phase gt
asset hmaxi-k overact bladder novemb roivant partnership cincinnati children hospit
medic center announc launch aruv scienc focu hematolog condit broader
genet medicin space april arbutu biopharma announc partner roivant launch jointly-
own genev scienc target rna-bas medicin use technolog includ rna interfer
rnai messeng rna mrna gene edit note roivant januari bid acquir phaserx
develop mrna product rare liver defect file bankruptci
ophthotech corpor februari announc collabor umm hora gene therapi center
develop aav-bas therapi use minigen approach potenti target leber congenit amaurosi lca
page
and/or stargardt diseas june ophthotech announc exclus licens agreement
univers florida upenn aav-bas silenc replac gt treat autosom domin retin
pigmentosa caus mutat rho gene octob ophthotech announc exclus option
agreement univers florida upenn preclin aav-bas gt treat best diseas
gene therapi efficaci durabl hit yr safeti system tox issu rais
us efficaci stori vivo gt emerg aav-bas gene therapi muscle-rel diseas
like duchenn muscular dystrophi dmd x-link myotubular myopathi xlmtm see
decemb abstract annual meet demonstr stabl therapeut express patient
sever hb period year import nathwani studi hemophilia increasingli show efficaci
indic requir system administr higher amount vector concern system toxic increas
inde aav-bas gt space stir gt pioneer dr jim wilson upenn research publish paper
discuss toxic seen high dose aav gt given intraven nonhuman primat gene therapi stock
trade paper warn featur time toxic reminisc innat immun respons
also note associ system inflamm advers affect previou gene therapi trial
addit commentari editori human gene therapi method also emerg cite limit paper
includ small per speci number anim treat possibl contamin batch use
and/or possibl find specif vector transgen human nhp use scienc
magazin follow januari publish commentari relat upenn human gene therapi public
februari forb publish interview dr wilson interview dr wilson provid context say
year field studi everi viral vector propos earli career
recent non-vir vector safeti profil aav respect immun toxic remark qualit better
experi deliveri platform
chang mind applic contempl still expect
pretti good safeti profil howev dose get high believ potenti dose limit toxic
think anyon surpris let impugn platform
end day best right dilig non-clin model determin
dose would see benefit similarli dose would see dose-limit toxic select diseas
unmet need signific would justifi risk despit anim model larg unknown
gene therapi compani increasingli use steroid mitig immunogen concern
sort system toxic discuss differ rel common safeti concern transaminas elev cell
respons seen number aav-bas gene therapi trial continu emphas howev per januari
uniqur research vector seem less immunogen like less cross reactiv neutral
antibodi type aav vector thu reduc need steroid trial gt notic
pattern compani use increas durat dose steroid mitig side effect associ
aav-bas gt suspect compani choos start aggress steroid use note follow
steroid-rel result phase i/ii trial accompani amend emphasi ad
audent therapeut phase i/ii aspiro studi xlmtm
page
octob busi updat call transcript decis made amend protocol extend
steroid coverag four week milligram per kilogram per day four-week taper eight week
milligram per kilogram per day eight-week taper prior enrol cohort expans patient may
associ lower frequenc group
januari patient also hospit week post-administr due gastrointestin infect
elev troponin level latter deem probabl treatment-rel respond
treatment intraven steroid administrationpati experienc clinic asymptomat elev liver
enzym level toward end protocol-specifi prednisolon wean period deem
probabl treatment-rel control extend durat steroid coverag
nightstar therapeut nsr-rpgr phase i/ii xiriu studi xlrp
novemb standard eight-week steroid regimen includ
septemb mild drug-rel inflamm potenti dampen efficaci seen treat
eye cohort treatment efficaci observ rescu patient receiv addit
regenxbio phase i/ii studi hofh
januari amend phase i/iia clinic trial protocol submit health author
allow enrol addit subject cohort dose use corticosteroid prophylaxi
august three subject cohort ii experienc elev transaminas week post-dosinga
t-cell respons may caus transaminas elev observ three subject cohort ii
trialadministr steroid appear mitig transaminas elev relat effect clinic
trial protocol expect amend enrol addit subject use steroid prophylaxi
solid bioscienc phase i/ii ignit dmd studi
june connect lift clinic hold solid made chang ignit dmd protocol
includ addit iv glucocorticoid initi week post administr enhanc
monitor measur includ panel complement activ amend protocol also specifi
eculizumab avail treatment option complement activ observ
march patient hospit due laboratori find includ decreas platelet count
follow reduct red blood cell count evid complement activ
spark therapeut phase i/ii studi hemophilia
decemb seven particip receiv taper cours reactiv administ oral steroid
includ five vg/kg cohort respons alanin aminotransferas alt elev
patient baselin declin fviii level and/or posit ifn-g enzyme-link immunospot elispot
particip steroid led rapid normal alt and/or elispotsw expect provid updat
phase studi includ addit vg/kg dose cohort five particip
dose materi suspens manufactur process also evalu prophylact rather
reactiv approach steroid administr goal reduc elimin immun respons
gene edit saw up down vivo crispr gene edit
mark volatil crispr space academ public rais calm concern safeti
 specul time also fuel perform particularli march highli controversi
paper publish natur method claim crispr edit introduc hundr unintend mutat mous
page
model formal retract retract accompani commentari sever gene edit compani
detail major scientif flaw retract paper later plo one public date juli use similar
studi design found signific off-target edit studi calm fear relat edit specif
addit paper rais new concern drive declin crispr compani paper nibr karolinska publish
june natur medicin suggest crispr edit may increas risk cancer edit cell enrich cell
defici activ tumor suppressor gene notabl paper look cell line
show edit actual led cancer juli studi wellcom sanger institut publish natur
demonstr crispr gene edit caus detriment dna damag even on-target site previou
studi focus damag off-target edit seri experi research show on-target
edit caus larg delet inappropri rearrang dna time even extrem specif
guid rna nucleas rais concern gene edit clinic set drive crispr stock
note june research clear whether issu report specif crispr may observ
nuclease-bas genom edit strategi well although compani incorpor
method detect chang standard workflow open question may seen posit compani
develop crispr-bas product reli dna break develop nuclease-
free platform logicbio therapeut homolog medicin use crispr technolog becom
ubiquit across academ research expect observ safeti paramet gene edit continu
emerg compani maintain focus safeti specif reiter view risk-benefit profil
given indic ultim determin suitabl crispr-bas therapi
past month mark substanti execut turnov helm public us crispr compani
past year crispr edita medicin intellia continu transit
exploratori early-stag biotech start-up more-focus clinical-stag compani accompani
manag turnov could contribut overal volatil seen gene edit space
januari edita announc presid ceo katrin bosley decid step role effect
decemb edita announc plan departur cfo andrew hack md phd return invest
octob privat announc adel nada md intellia vice-president head clinic develop
transit becom casebia
august edita announc gerald cox md phd step end
june intellia announc cfo graem bell resign effect august plan departur
mr bell could join octob intellia name glenn goddard cfo
march crispr announc retir chief legal offic tyler dylan-hyd phd jd shelbi
walker jd appoint head intellectu properti
februari crispr announc transit lundberg md cso head crispr
scientif advisori board successor appoint
decemb intellia announc januari departur ceo nessan bermingham phd return
ventur capit industri john leonard md appoint ceo
despit excit gene edit progress particularli vivo sluggish decemb
review highlight arriv gene edit clinic treat human diseas initi
phase i/ii clinic trial vivo aav-bas zinc finger nucleas zfn gene edit asset mucopolysaccharidosi
page
type ii mp ii hunter syndrom novemb crispr therapeut togeth partner vertex
pharmaceut announc submiss cta ex vivo gene edit asset beta thalassemia
decemb edita intellia advanc respect program expect trial start
respect year later progress made anticip catalyst come fruition
sangamo gene edit program clinic readout anticip notabl although
sangamo present data mp ii program septemb demonstr favor safeti profil
substrat biomark chang suggest success edit definit evid vivo gene edit yet
shown crispr clinic trial recruit patient beta thalassemia sickl cell
diseas scd europ us respect howev clinic hold place compani scd program
announc may announc lift octob slow momentum push
guidanc ind submiss octob edita activ ind aav-bas vivo
gene edit therapeut leber congenit amaurosi type howev januari patient dose
expect begin intellia similarli revis guidanc ind submiss lead vivo gene edit
asset transthyretin amyloidosi attr order incorpor technolog advanc
develop cours year thu vivo crispr-bas gene edit program continu lag behind ex vivo
asset us unexpect power technolog get preclin proof concept fast howev
process systemat refin preclin tool clinical-grad therapeut necessit extens
test particularli true therapeut involv vivo edit opportun qualiti control
 transfer edit cell patient accumul clinic data compani use compet modal
 rnai base therapeut alnylam proqr attr respect vivo ge therapi need
demonstr robust safeti profil durabl efficaci compet limit patient number rare indic
clinic hold regulatori setback may frustrat crispr babi saga underscor import
oversight novemb chines scientist jiankui claim produc first germline-edit human
babi video post youtub provok immedi sharp critic scientist clinician regul
present gene edit summit hong kong addit detail clinic studi reveal disturb lack
clinic transpar well scientif rigor studi describ genet vaccin goal edit
gene vitro fertil ivf mimic naturally-occur variant shown restrict hiv
entri cell base data present neither twin girl born result ivf actual exact
resist variant rather differ variant gene may may protect
hiv function entir uncharacter hiv certainli potenti devast diseas unmet
medic need avail prevent treatment option render disrupt inappropri candid
approach degre risk despit extens basic translat research last sever year field
gene edit particularli crispr space still earli stage modal highli public controversi
still potenti set entir field back dramat also case china ahead us
europ bring crispr clinic clinic trial evalu crispr-edit car-t cell variou cancer
current list clinicaltri gov given continu expans translat research asia rise number
biotech ipo hong kong expect see rigor oversight program move forward inde
note recent announc januari world econom forum annual meet davo
intern commiss address issu around germlin gene edit
page
gene edit new crispr technolog emerg therapeut diagnost use
saw evid base edit could util certain applic per may announc
therapeut launch mm rais seri round licens harvard univers crispr-bas edit
technolog develop laboratori david liu feng zhang keith joung unlik typic crispr-bas edit
gene mutat creat via imperfect repair break induc dna base edit interconvert individu
dna base base pair without make double-strand dna break util base edit therefor highest
condit involv point mutations sickl cell anemia hemochromatosi februari circul articl
proof-of-concept base edit emerg research upenn demonstr reduc blood lipid level
vivo base edit inactiv gene mice similarli natur medicin public
date octob research zurich show metabol improv mous model phenylketonuria
vivo base edit correct mutat pah gene recent concern highlight surround safeti dna
break induc crispr could enhanc demand technolog howev like new technolog base edit
doubt requir optim take lab clinic instanc recent pre-peer review paper post
novemb biorxiv found higher incid off-target mutat induc mous embryo use crispr
base editor compar typic nucleas
also show util crispr technolog diagnost purpos crispr technolog also tap
develop simpl diagnost could effect deploy field case viral outbreak
perform home trio paper publish journal scienc april broad institut uc
berkeley demonstr use enzym also known detect dengu zika
human papillomaviru high sensit berkeley group launch mammoth bioscienc around technolog
call detectr goal develop rapid inexpens paper-bas method genet test infecti
diseas detect technolog broad institut call sherlock develop similar goal anoth
broad institute-found compani arbor biotechnolog publish april studi character new small
protein potenti vivo applic use proprietari platform high-throughput enzym discoveri
rnai onpattro first rnai therapeut approv clinic data drive smaller cap
new era begin first rnai therapeut onpattro approv us europ august fda
announc onpattro patisiran approv use adult patient treatment
peripher nerv diseas polyneuropathi caus hereditari transthyretin-medi amyloidosi hattr onpattro thu
becam small interf ribonucl acid sirna therapeut approv fda onpattro also receiv market
author throughout european union august broader genet medicin space onpattro
approv continu regulatori momentum space first us gene therapi approv occur
name ex vivo gene-modifi cell therapi cancer kymriah august yescarta octob
vivo gene therapi luxturna decemb
move rnai compani share price driven studi result march posit top-line result
anticip data phase trial vyndaqel tafamidi transthyretin cardiomyopathi
attr-act may driven drop share
around time akcea/ioni alnylam develop tegsedi onpattro
respect approv benefit numer present
page
year posit interim data phase i/ii program target hepat aro-hbv liver diseas aro-att
present includ hepat data easl april interim hepat data world gastroenterologist
summit septemb liver diseas data nation educ confer june
collect dataset drove share price decemb peak septemb
final price decemb septemb proqr present posit
interim result phase i/ii trial sepofarsen leber congenit amaurosi retin
degener meet killarney ireland prqr share close septemb
decemb peak novemb finish proqr expect
advanc sepofarsen phase ii/iii pivot trial per septemb research kol felt proqr
data promis challeng patient group also note rna-bas oligonucleotid differ technolog
gene augment could appli target gene proqr enter phase i/ii studi usher
syndrom type gener interim data neg side juli
announc paus phase studi autosom domin polycyst kidney diseas adpkd
unexpect observ mous chronic toxic studi juli compani share close
close price juli rgl share finish octob arbutu biopharma
announc setback develop hbv rna de-stabil compound expect enter clinic
due toxic issu identifi preclin studi addit arbutu rnai compound target
hbv compani previous indic would advanc demonstr poor result
combin studi updat saw abu share close octob
decemb abu share finish
collabor rna medicin also abund like driven result follow progress pipelin
arrowhead octob announc collabor agreement janssen pharmaceut part johnson
johnson arrowhead receiv mm up-front payment plu mm equiti invest exchang
world-wide exclus licens aro-hbv option collabor new target april dicerna
pharmaceut announc agreement alnylam thu resolv litig disput compani
remov overhang stock octob octob dicerna announc collabor
agreement alexion focus preclin galxc rnai molecul target complement-medi diseas
focus preclin galxc rnai molecul target area cardio-metabol diseas neurodegener pain
respect collect dicerna receiv up-front payment million plu equiti invest million
alnylam march announc collabor regeneron develop therapi nonalcohol steatohepat
nash us strong valid signal potenti robust safeti rnai even mass-market indic
januari arcturu curevac announc collabor agreement develop molecular therapi product
rare diseas use curevac optim natur mrna sequenc rna optim arcturu lipid-medi nucleic
acid deliveri system lunar first program target ornithin transcarbamylas over-the-counter defici expect
enter clinic januari proqr announc collabor galapago develop therapi
fibrosi use proqr axiom technolog april arbutu roivant scienc partner launch genev
scienc focus develop broad rang rna-bas therapeut goal candid
clinic genev juli announc partnership discov mrna-bas therapeut
rare diseas
page
review datasetsselect clinic gm dataset trial first report
us known muscl emerg viabl primari tissu target aav-bas gt includ trial
newli report oppos updat prior year exclud dataset ex vivo engin immun cell
januari may august octob audent report posit data phase
i/ii aspiro studi xlmtm aav-bas gt earli result show breakthrough efficaci
sae caus concern updat demonstr associ sae breakthrough efficaci continu
high protein express shown muscl biopsi
januari septemb announc result phase i/ii studi
aav-bas gt over-the-counter defici updat result show normal ureagenesi patient
march april ioni roch announc phase i/ii dose escal studi ionis-
htt rx demonstr signific dose-depend reduct mutant huntingtin mhtt protein
cerebrospin fluid early-stag huntington diseas patient
march vbl therapeut announc phase globe trial adenovirus-bas gt
recurr glioblastoma rgbm fail meet primari endpoint overal surviv os
aav-bas gene therapi gt leber hereditari optic neuropathi lhon
treat eye saw gain studi fail meet primari endpoint untreat eye saw similar benefit
extens explor natur histori result givosiran acut hepat porphyria ahp result
show continu givosiran dose lead reduct diseas marker ala pbg
april agili part present follow-up result
pediatr patient treat aav-bas gt agil-aadc aadc defici patient shown
improv motor function achiev unassist sit achiev assist stand
april avexi part novarti present first interim data pivot trial
zolgensma sma type april cutoff chop-intend score patient improv
averag point month treatment patient show increas point month post-treat
may audent report phase i/ii valen result aav-bas gt
crigler-najjar syndrom first patient treat reduct bilirubin within week level return
pre- treatment baselin week
may abeona report phase i/ii data autolog ex vivo gt treat
recess dystroph epidermolysi bullosa rdeb studi met primari endpoint safeti toler
preliminari efficaci compar data heal untreat wound support natur histori studi
may present data phase i/ii studi aav-
base gt treat sanfilippo syndrom type mp patient maintain dose-depend reduct biomark
includ heparin sulfat csf urin seriou drug-rel advers event observ
may spark announc result patient phase i/ii studi
aav-bas gt hemophilia patient treat product manufactur use enhanc process
updat data previously-tr patient patient factor ix activ level normal
new patient activ
page
june bluebird bio announc data phase i/ii trial lentivir gt lentiglobin
transfusion-depend beta-thalassemia tdt show patient maintain transfus independ
median month studi show optim manufactur process yield higher
vector copi number transduct percentag versu origin process
june octob sarepta report preliminari result phase i/ii trial aav-bas
gt micro-dystrophin dmd demonstr breakthrough result measur micro-dystrophin express
updat result confirm earli efficaci patient includ robust protein express muscl biopsi
june novemb present data phase studi
rnai therapeut aro-aat updat result show sustain knockdown healthi volunt
august decemb spark report phase i/ii trial result aav-bas gt
hemophilia mean factor viii activ reach therapeut level patient highest dose cohort
immun respons caus concern updat data indic reduct abr/air across cohort
august octob announc posit interim data phase trial
wet show dose-depend protein express well reduct anti-vegf inject phase
i/ii trial data homozyg famili hypercholesterolemia show transaminas elev
septemb octob announc proof-of-concept result phase trial
rnai therapeut dcr-phxc primari hyperoxaluria patient show clinically-meaning
reduct urinari oxal updat result show normal near-norm treat patient
septemb proqr present interim phase i/ii data rna-bas oligonucleotid
patient leber congenit amaurosi month treatment subject show
improv best correct visual acuiti greater logmar baselin clinic meaning
septemb present data phase i/ii trial vivo gene
edit ge -base therapeut mp ii treatment well toler show biomark
improv intermedi dose lack detect transgen express rais market concern
septemb novemb arrowhead pharmaceut report result phase i/ii trial
rnai therapeut aro-hbv hbv infect updat result demonstr hbsag reduct log
septemb octob amicu present data phase i/ii studi
batten diseas data patient treat show sign efficaci
septemb nightstar report interim data phase i/ii studi aav-bas
gt nsr-rpgr x-link retin pigmentosa xlrp preliminari result show improv microperimetri
higher-dos cohort show ild drug-rel inflamm potenti dampen efficaci
septemb novemb ioni announc data phase ii
trial akcea-apo -lrx patient establish cardiovascular diseas cvd elev level
lipoprotein lp trial met primari secondari efficaci endpoint month treatment
septemb announc top-line result interim analysi phase envis
trial rnai therapeut givosiran ahp data show signific reduct surrog
biomark ala howev sae seen treat patient compar placebo group
septemb gen present preliminari data phase ib trial rrv-base gt
 fc advanc solid tumor analysi peripher blood tumor sampl show immun cell
modul consist preclin data evid vector penetr tumor microenviron
page
octob announc data phase phase i/ii studi ex
vivo lentivir gt fabri diseas share close sinc seen slide present
overal downward trend aga enzym activ month may rais concern durabl
octob arbutu biopharma announc patient treat rnai therapeut hbv
meet respons criteria proceed per protocol peg-interferon treatment
octob report earli data patient treat phase i/ii trial
dystroph epidermolysi bullosa deb met primari safeti efficaci endpoint treat wound
close within week stay close placebo-tr wound took week fail close complet
octob announc phase ib/ii data danvatirsen gener antisens therapi
target combin astrazeneca antibodi durvalumab recurr metastat head
neck cancer data show respons rate approxim doubl versu certain studi durvalumab alon
novemb report discontinu develop gt
defici due lack therapeut protein express phase i/ii advanc trial
maxim protein level studi lower therapeut threshold
novemb decemb uniqur announc phase iib dose-confirm studi data
aav-bas gt hemophilia mean factor ix activ across patient week post-dos
compani later report activ continu rise updat result year phase i/ii studi
also continu show benefit
decemb bluebird bio announc phase trial data patient treat
lentiglobin ex vivo gt tdt patient genotyp hemoglobin
decemb bluebird bio announc phase i/ii data ex vivo gt lentiglobin sickl
cell diseas patient treat patient group month post treatment total hemoglobin rang
g/dl compani note patient group develop myelodysplasia syndrom sae
decemb freelin present phase i/ii b-amaz trial data aav-bas gt hemophilia
 treat patient achiev factor ix activ week sustain month
decemb orchard therapeut present clinic proof-of-concept data patient phase i/ii studi
ex vivo lentivir gt sever x-link chronic granulomat diseas x-cgd
evalu patient show sustain function neutrophil level rang month post treatment
exce clinic benefit threshold believ necessari restor immun function
decemb wave life scienc report posit top-line phase result dmd
decemb agtc report discontinu develop gt x-link
retinoschisi xlr top-line interim data result phase i/ii clinic trial show
fail exhibit clinic activ month treat patient
review collaborationsselect newly-announc gm collabor
januari sangamo collabor zinc finger protein gt amyotroph later sclerosi al
frontotempor lobar degener ftld link mutat gene
januari johnson johnson announc collabor upenn aav-bas alzheim diseas
januari proqr announc collabor galapago develop therapi fibrosi use
page
januari novarti announc licens suppli agreement spark luxturna
market outsid us notabl deal includ mm up-front fee mm upcom mileston mid-
percentag royalti spark significantli de-risk ex-u roll-out luxturna spark
februari oxford biomedica announc collabor licens agreement bioverativ part
sanofi regard lentivir vector hemophilia oxb may receiv mileston worth excess million
plu undisclos royalti net sale bioverativ lentivir vector haemophilia product
februari voyag enter collabor agreement develop aav-bas therapi
alzheim diseas voyag receiv million up-front payment plu potenti billion
payment relat preclin clinic regulatori mileston
februari ophthotech univers massachusett medic school hora gene therapi center enter
collabor gene therapi rare inherit retin diseas like stargardt diseas
march regeneron announc plan enter co-develop
commerci arrang therapeut product candid emerg discoveri effort
april arbutu biopharma roivant scienc partner launch genev scienc
april glaxosmithklin gsk sign agreement transfer rare diseas
transfer includ approv strimv clinic asset well right licens preclin program deal
give gsk equiti ownership orchard
april ioni pharmaceut expand partnership develop antisens oligonucleotid
neurolog diseas accord term agreement pay ioni bn cash includ
mm purchas mm ioni share mm up-front payment
april molecular therapeut expand partnership roch includ multipl aav-bas
product ophthalmolog molecular conduct earli discoveri studi includ early-stag clinic develop
roch conduct late-stag studi well global commerci product
may sarepta announc partnership myonexu limb-girdl muscular
dystrophi part announc term sarepta grant exclus option acquir myonexu
may lonza enter exclus option agreement explor use novel capsid
librari develop massachusett potenti licens
june axov licens axo-lenti-pd oxford biomedica axov receiv mm equiti
financ roivant scienc support clinic develop axo-lenti-pd program
june ophthotech enter exclus licens agreement univers florida univers
pennsylvania develop gt rhodopsin-medi autosom domin retin pigmentosa
juli axov licens axo-aav-opmd plu addit gt product neurolog condit benitec
biopharma exchang up-front payment mm plu mileston payment benitec receiv
net profit world-wide sale axo-aav-opmd tier royalti gt product
juli molecular therapeut medimmun biolog arm astrazeneca announc collabor
develop commerci chronic lung diseas use platform gener optim aav vector
respons vector develop medimmun respons clinic stage product develop
juli genev scienc announc partnership develop mrna-bas therapi
august akcea collabor commerci tegsedi waylivra latin america
august sarepta enter licens agreement long-term strateg invest lacerta
therapeut multipl also access gt talent tool
page
septemb precis bioscienc announc partnership gilead scienc develop therapi
hepat viru hbv use precis genom edit approach precis elig receiv mileston
payment mm mid-teen tier royalti commerci product partnership
septemb viacyt announc collabor develop gene-edit stem cell-bas
therapeut diabet compani share cost profit world-wide
octob janssen pharmaceut compani johnson johnson enter exclus world-wide licens
agreement develop commerci aro-hbv chronic hbv infect
octob sarepta licens aav-bas gt charcot-marie-tooth neuropathi global
common inherit neuromuscular disord nationwid children hospit
octob exclus licens mp iiia lysogen right option
second gt candid lysogen receiv million close potenti futur mileston total
approxim million million sales-bas royalti
octob meiragtx announc research collabor evalu agreement janssen
pharmaceut one pharmaceut compani johnson johnson use meira riboswitch technolog
engin regulat gene therapi construct encod proprietari gene sequenc janssen
octob announc exercis option exclus world-wide
licens vector includ defici disord cdd return receiv
up-front payment on-going fee mileston payment royalti net sale product incorpor vector
octob strike deal use dicerna galxc technolog
develop rnai therapi complement pathway-medi diseas option exercis fee mm per
molecul dicerna also receiv mm up-front payment addit mm equiti invest alexion
deal potenti addit payment mm includ exercis fee mileston royalti payment
octob announc collabor agreement develop rnai-bas
therapi compani expect explor target within neurodegener pain space well
select cardio-metabol diseas dicerna receiv mm up-front well mm equiti invest
dicerna may receiv approxim mm/target development commerci mileston
octob meiragtx announc exclus licens agreement nation institut dental
craniofaci research nidcr divis nih meira receiv world-wide right
sjgren syndrom associ xerostomia xerophthalmia
octob ophthotech enter exclus licens agreement univers florida univers
pennsylvania develop gt best vitelliform macular dystrophi
novemb announc licens agreement grant abeona
exclus world-wide licens vector treatment sanfilippo syndrom type mp iiia sanfilippo
syndrom type mp iiib infantil batten diseas diseas juvenil batten diseas diseas return
receiv mm up-front payment mm annual fee mm guarante
mm commerci mileston payment low double-digit royalti net sale product
novemb regenxbio enter exclus world-wide licens agreement
gt treatment danon diseas use vector return receiv mm up-front
payment plu on-going fee mileston payment high-singl low-doubl digit royalti net sale
decemb termin collabor agreement agtc return right clinic program
decemb axov licens gangliosidosi tay-sachs/sandhoff diseas umass ms
page
review bn select gm equiti offer ipo secondari
corpor report chardan chang name
figur select genet medicin ipo rais bn secondari offer rais bn total offer bn
page
review aroughli bn select gm relat activ
januari complet merger
januari celgen announc acquisit approxim billion
februari astella acquir gene-edit stem cell compani univers cell mm
march sanofi acquir bioverativ origin spin-out bn
april avexi enter definit agreement acquir novarti deal worth total bn
juli announc acquisit mm up-front mm cash
mm stock plu mm mileston plu potenti royalti
august astella announc acquisit quethera approxim mm
septemb amicu acquir aav-bas gt compani celenex mm
page
review stock price decemb vs decemb
corpor report factset chardan note mention stock unrat unless otherwis state public unrat unless state gt compani includ
benitec biopharma fibrocel oncosec medic oxford biomedica lysogen vbl buy
figur select price movement vivo gt aav-bas gt driven avexiss perform
page
perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin vivo cap vector-bas gene therapytickerratingccm ptupsideclosechang changemc mm genet small rna therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
review monthli market cap progress
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
chardan anticip theme vivo gt
look ahead rest expect see
regulatori support gene therapi broader genet medicin space continu
expect aav-bas gt continu success seen recent year
label price reimburs uptak zolgensma sma type may broadest implic
potenti breakthrough one-tim gt product
number privat compani taken view much fewer qualiti academ asset avail
licens acquir expect new entrant aav-bas gt space acquir partner exist
player support potenti recent collabor announc voyag therapeut januari
meiragtx januari
dataset expect muscl stori dmd xlmtm continu expect see
signific progress muscl diseas like pomp diseas clinic studi variou
muscular dystrophi myoton facioscapulohumer preclin studi believ scope exist
heart emerg viabl primari target aav-bas gt note per januari
releas plan start phase trial danon diseas monogen heart failur syndrom
pivot hemophilia biomarin hemophilia uniqur trial on-going sinc compani use
similar vector manufactur uniqur ip right pivot readout biomarin could caus market
interest uniqur ahead compani pivot readout
progress wet could dictat whether aav-bas gt target rare
monogen diseas also large-market indic discuss program februari
encourag investor attent compani show even preclin progress re-dos strategi
also strategi address dilut effect enabl treatment pediatr popul
expect see steroid use proactiv reactiv trial address immunogen concern
gene edit outsid cancer indic ex vivo vivo dataset could drive sector perform
ind activ gene-edit hematopoiet stem cell therapi sickl cell diseas scd beta
thalassemia crispr therapeutics/vertex sangamo
therapeutics/bioverativ sanofi compani expect first data
program emerg year possibl data stack bluebird bio
lentiglobin ex vivo lentivir gene therapi indic like dictat market enthusiasm
follow-on ex vivo gene edit program abil compani platform deliv
arguabl anticip ex vivo data first definit human vivo gene edit readout
anticip sangamo current phase activ i/ii program use aav-bas zinc finger nucleas
zfn edit technolog mucopolysaccharidosi type
mucopolysaccharidosi type ii mp ii sb-fix hemophilia
compani present biomark data mp ii program septemb data includ
sequenc assay detect transgene-deriv enzym level definit evid vivo edit sangamo
host call discuss vivo program februari expect aspect data roll
possibl earli readout ocular gene edit program
leber congenit amaurosi expect enter phase i/ii trial readout may
page
serv bellweth vivo gene edit space term safeti signal expect efficaci achiev
vector dose current use aav-bas therapeut
addit aav-bas vivo gene edit program best case could enter
clinic well could affect investor think edit platform
expect autoimmun inflammatori indic obviou next step engin immun cell
therapi take advantag learn car-t scienc manufactur may exemplifi
sangamo octob announc acquisit txcell car-regulatori cell car-treg program
sangamo hope build autoimmun franchis larg market potenti also
indic plan develop therapeut autoimmun diseas
look forward updat compani gene edit program target tissu stem cell thu expand
past low-hang fruit hsc stem cell type theme support sever collabor
announc expect hear note decemb intellia
novarti announc expans partnership gener crispr-bas therapeut use ocular limbal
stem cell septemb crispr viacyt announc collabor gene-edit
embryon stem cell-deriv therapi type diabet august toolgen nsage new york
stem cell foundat announc partnership develop stem cell base therapi leav edita
public crispr compani without disclos next-gen stem cell program understand carib bioscienc also
develop crispr edit program base induc pluripot stem cell ipsc
expect see movement toward form intern commiss ultim develop
framework robustli address ethic issu gene edit gene edit embryo
synthet biolog increas import therapeut space note januari chardan
synthet biolog kol call dr jame collin synthet biolog strong posit affect cell gene therapi
near term although field quit young decad element synthet biolog increasingli
enter develop pipelin genet medicin space creat control tune therapeut activ
level dna rna protein note number import applic oncolog
effort on-going make next-gen cell therapi safer effect solid tumor includ use suicid
switch caspacid use bellicum use poseida therapeut enabl elimin
cell event cytokin releas syndrom mechan induc activ administr small
molecul bellicum obsidian cellecti also present data talen-bas insert
immune-stimulatori cytokin locu car-t cell dynam convert inhibitori signal
activ one effort engin smart cell-bas therapi incorpor logic gate
develop senti given limit efficaci seen solid tumor thu far believ advanc
featur may necessari expand util cell-bas immunotherapi beyond blood cancer
cell-bas therapi repres lower hang fruit synthet biolog due rel eas
engin gene circuit ex vivo use induc transgen express appli vivo well
exampl ziopharm oncolog rheoswitch-bas control therapi phase trial
glioblastoma meiragtx also induc gt express technolog riboswitch develop
synthet biolog also appli outsid convent genet medicin space
develop synthet biotic base probiot coli nissl engin gene circuit see
decemb research produc therapeut metabol diseas immuno-oncolog
page
product phase i/ii trial hepat encephalopathi phenylketonuria see
leader bring synthet biolog genet medicin space
expect incorpor artifici intellig ai genet medicin design analysi coupl
recent natur paper novemb novemb discuss predict dna repair outcom crispr
gene edit use machin learn signific repair edit site without homolog repair
templat gener thought occur randomli small insert delet dna base occur
target edit site disrupt desir gene sequenc paper relev relat highli public paper
regard crispr off-target effect possibl link cancer studi exampl show machin learn
algorithm train dataset thousand guid rna/target pair could predict type outcom expect ai
therefor increasingli incorpor design workflow gene edit asset along now-ubiquit
assay predict detect off-target edit ai cours also appli area genet medicin
dyno spin-out georg church lab wyss institut harvard use machin learn
develop librari aav vector novel therapeut properti broader capabl artifici intellig
investor enthusiasm surround technolog continu grow expect see incorpor machin
learn form ai design next-gen genet medicin
rnai expect clinic dataset figur figur continu drive perform
chardan bold predict uniqur get acquir reach bn market cap
reiter januari research reason uniqur chardan top pick chardan genet medicin
top pick name base first- best-in-class profil gene therapi gt
hemophilia pivot phase data due uniqur possess value-cr manufactur ip asset
uniqur high product exposur advanc gt technolog synthet biolog likelihood uniqur
acquir perhap biomarin unrat research detail reason
page
viral news genet medicin chardan publish research
viral news gene therapi breakthrough year end luxturna approv
viral news gene therapi luxturna price new payor model
viral news gene therapi compani provid guidanc beyond
viral news gene therapi first us crispr trial approach
viral news gene therapi large-cap interest juno drive sector
viral news gene therapi patisiran approv expect august
viral news gene therapi gene edit acquisit immin
viral news genet medicin oxb toolgen drive basket alpha
viral news genet medicin thesi support via gild/sgmo deal
viral news genet medicin opht turn gt edg
viral news genet medicin flurri result vector gt
viral news genet medicin hold new rna-bas medicin deal
viral news genet medicin luxturna launch upgrad rnai rate
viral news genet medicin crispr off-target retract calm fear
viral news genet medicin kite veteran back allogen
viral news genet medicin novarti buy avexi gsk orchard partner
viral news genet medicin receiv fda letter partial hold lift
viral news genet medicin new f/u data agili avx
viral news genet medicin prv rpdd creat tangibl sector valu
viral news genet medicin earn domin ahead asgct data readout
viral news genet medicin introduc chardan gene edit framework
viral news genet medicin fda show support effect gene therapi
viral news genet medicin genet screen place
viral news genet medicin axov ophthotech move gt
viral news genet medicin nite get rmat crispr paper appear
viral news genet medicin aav-bas break dmd
viral news genet medicin chardan top pick show trial progress
viral news genet medicin patisiran domin inotersen nejm
viral news genet medicin fda draft guidelin support disrupt
viral news genet medicin acquir agili
viral news genet medicin clinic hold emerg sarepta
viral news genet medicin onpattro grant earli access uk
viral news genet medicin onpattro approv bold/once/rgnx report data
viral news genet medicin esrx distribut gt rac review elimin
viral news genet medicin opht publish silence-and-replac pc data
viral news genet medicin onpattro approv eu crsp enter clinic
viral news genet medicin mount momentum rna therapi
viral news genet medicin kol posit potenti gt use xlrp
viral news genet medicin buy gt nite xlrp data emerg
viral news genet medicin get top-line data hold lift
viral news genet medicin bold provid updat result
viral news genet medicin crsp us scd trial go expand gt
viral news genet medicin esgct data readout report pi/ii data
viral news genet medicin data show protein express mo
viral news genet medicin termin gt
viral news genet medicin cost million
viral news genet medicin qure report data dose pt
viral news genet medicin qure new luxturna author eu
viral news genet medicin collaboration-rel news abund
viral news genet medicin qure show increas activ past yr
viral news genet medicin chardan publish human gene therapi
viral news genet medicin cost effect spinraza
figur chardan publish viral news genet medicin report
page
chardan top pick genet medicin avx alpha sinc
figur chardan top pick genet medicin cumul gener absolut rel return sinc march
page
datedategtgtchardan genet medicineschardantop pickstocknbitop pickstocknbistocknbistocktop pick sinc open stock data market genet medicin cumul perform top pickrelativeperform alpha versu nasdaq biotech nbi pharmaceut
chardan genet medicin top pick qure average alpha
figur chardan genet medicin top pick qure averag absolut rel perform
page
datedategtgtchardan gene therapychardantop pickstocknbitop pickstocknbistocknbistocktop pick genet medicin top pick qure rel ytd perform alpha versu nasdaq biotech pharmaceut
chardan genet medicin top pick avx average alpha
figur chardan genet medicin top pick avx averag absolut rel perform
page
datedategtgtchardan genet medicineschardantop pickstocknbitop pickstocknbistocknbistocktop pick pharmaceut genet medicin top pick avx rel ytd perform alpha versu nasdaq biotech pharmaceut
figur chardan genet medicin pair trade averag alpha gener success rate sinc juli
page
chardan genet medicin pair tradesdategmgmpairopen open stock data market priceopen priceprefer rate time genet medicin perform publish pair tradesrel perform alpha long versu short averagel agtc sh aavll aavl sh dmtxl agtc sh dmtxl qure sh dmtxl sh dmtxl qure sh sh sh avx sh qure sh oncel sh oncel aav sh gel sh nbil agtc sh aavl sh aavl sh dmtx sh dmtx agtc sh dmtx qure sh dmtx aav sh ge avx sh gmpairtrad qure sh sh sh nbi qure sh sh pharmaceut
select catalyst genet medicin coverag
provid follow-up data piib dose-confirm studi hemb
axo-lenti-pd report data first patient sunrise-pd phase i/ii trial
present data immun mechan action ovarian cancer
givosiran report top-line data envis piii trial acut hepat porphyria ahp
dcr-hbv initi clinic trial hepat viru pend cta approv
provid initi data phase trial tay-sachs/sandhoff diseas
provid top-line result phase rescu trial lhon
submit ind chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
report preliminari muscl biopsi result phase i/ii ignit dmd trial dmd
dcr-phxc initi phase ii/iii primari hyperoxaluria pend regulatori feedback
initi patient dose hope-b phase trial hemophilia hemb
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
provid continu regulatori updat x-link myotubular myopathi xlmtm
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
present updat clinic data xlmtm
provid program overview undisclos larg neuromuscular diseas
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
report result piii revers trial result piii rescu trial lhon
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
complet enrol dose escal phase i/ii trial achm
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii gem studi dystroph epidermolysi bullosa deb
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
provid data interim analysi phase i/ii ignit dmd trial dmd
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
initi phase i/ii clinic trial huntington diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjgren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meiragtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
report phase i/ii interim data mp ii worldsymposium
provid data updat phase ii trial fabri diseas
begin dose patient investigator-sponsor phase i/ii trial cystinosi
submit ind infantil batten diseas
report interim phase ii data recess dystroph epidermolysi bullosa
initi phase dose escal studi danon diseas
initi phase trial recess dystroph epidermolysi bullosa
 anticip data readout phase trial hd
initi phase ii trial multipl tumor type
begin patient dose phase trial
submit ind relapsed/refractori non-hodgkin lymphoma r/r nhl
aft spear cell report data phase trial hepatocellular carcinoma
initi clinic trial fanconi anemia use process product
submit ind gangliosidosi
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
bmn file ind phenylketonuria pku
provid dystrophin data phase trial dmd
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
figur plan file bla aadc defici
page
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani lead program phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid technolog
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet technolog pharmaceut
genet medicin therapeut approv fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
